The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium *
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A three-line (15-letter) change in BCVA has traditionally been accepted to represent a clinically significant impact in interventional trials assessing the effectiveness of drugs where there is an inherent benefit:risk ratio to be considered.26”
From ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2 (2024) · cites this paper as [26]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Fung, A. E., Lalwani, G. A., Rosenfeld, P. J., Dubovy, S. R., Michels, S., Feuer, W. J., Puliafito, C. A., Davis, J. L., Flynn, H. W., & Esquiabro, M. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.01.028 · Cited by 972
GILLIES, M., SUTTER, F., SIMPSON, J., LARSSON, J., ALI, H., & ZHU, M. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.02.065 · Cited by 425
Vascular Endothelial Growth Factor Is a Critical Stimulus for Diabetic Macular Edema
Nguyen, Q. D., Tatlipinar, S., Shah, S. M., Haller, J. A., Quinlan, E., Sung, J., Zimmer-Galler, I., Do, D. V., & Campochiaro, P. A. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.06.068 · Cited by 351
Retinal Microaneurysm Counts and 10-Year Progression of Diabetic Retinopathy
Klein, R. (1995) · Archives of Ophthalmology · doi:10.1001/archopht.1995.01100110046024 · Cited by 156
Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease
Aylward, E. (2006) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2006.10.028 · Cited by 121
Macular Edema in Diabetic Retinopathy Study Patients
Ferris, F. L., Podgor, M. J., & Davis, M. D. (1987) · Ophthalmology · doi:10.1016/s0161-6420(87)33526-2 · Cited by 114
Self-citationVisual fields correlate better than visual acuity to severity of diabetic retinopathy
Bengtsson, B., Heijl, A., & Agardh, E. (2005) · Diabetologia · doi:10.1007/s00125-005-0001-x · Cited by 72
VANDER, J. F. (2007) · Yearbook of Ophthalmology · doi:10.1016/s0084-392x(08)70105-9 · Cited by 46
Posterior Sub-Tenon Triamcinolone for Refractory Diabetic Macular Edema: A Randomized Clinical Trial
Entezari, M., Ahmadieh, H., Dehghan, M., et al. (2005) · European Journal of Ophthalmology · doi:10.1177/112067210501500614 · Cited by 36
Cited by
Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT
Sadda, S. R., Guymer, R., Holz, F. G., Schmitz-Valckenberg, S., Curcio, C. A., Bird, A. C., Blodi, B. A., Bottoni, F., Chakravarthy, U., Chew, E. Y., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.09.028 · Cited by 922
Self-citationOwsley, C. (2011) · Vision Research · doi:10.1016/j.visres.2010.10.020 · Cited by 701
Holz, F. G., Strauss, E. C., Schmitz-Valckenberg, S., & van Lookeren Campagne, M. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.11.023 · Cited by 402
Edelhauser, H. F., Rowe-Rendleman, C. L., Robinson, M. R., Dawson, D. G., Chader, G. J., Grossniklaus, H. E., Rittenhouse, K. D., Wilson, C. G., Weber, D. A., Kuppermann, B. D., et al. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-5392 · Cited by 262
Self-citationGene Editing for CEP290 -Associated Retinal Degeneration
Pierce, E. A., Aleman, T. S., Jayasundera, K. T., Ashimatey, B. S., Kim, K., Rashid, A., Jaskolka, M. C., Myers, R. L., Lam, B. L., Bailey, S. T., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309915 · Cited by 237
Metadata
- Authors
- Csaky, K. G., Richman, E. A., & Ferris, F. L.
- Affiliations
- Duke Medical Center (US)
- Richman Associates, LLC, Baltimore, Maryland; and the
- National Institutes of Health (US)
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2008-02-01
- Volume
- 49
- Issue
- 2
- Pages
- 479
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W1997000986
- Cited by
- 265
- References
- 16
- Citations by year
- 2026: 17 · 2025: 26 · 2024: 22 · 2023: 10 · 2022: 15 · 2021: 16 · 2020: 16 · 2019: 13 · 2018: 9 · 2017: 17 · 2016: 17 · 2015: 13 · 2014: 13 · 2013: 9 · 2012: 10
- FWCI
- 12.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Food and Drug Administration
- National Eye Institute
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Visual Impairment Studies
- Keywords
- ophthalmic clinical trials, clinical trial design, clinical trial endpoints, ophthalmic drug development
- MeSH terms
- Atrophy, Clinical Trials as Topic, Diabetic Retinopathy, Humans, Macular Degeneration, National Institutes of Health (U.S.), Ophthalmology, Pigment Epithelium of Eye, Product Surveillance, Postmarketing, Research Design, United States, United States Food and Drug Administration, Visual Acuity, Treatment Outcome, Patient Satisfaction, Choroidal Neovascularization, Endpoint Determination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.